Scynexis Switches Focus To Hospital Indications For Ibrexafungerp
Executive Summary
With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.
You may also be interested in...
FDA Turns Down F2G’s Antifungal, But Firm Plots Comeback As Trial Completes Accrual
The US regulatory agency asked for more data and analyses for olorofim, which F2G hopes to provide from an ongoing Phase IIb study.
GSK Boosts Its Infectious Disease Portfolio With Brexafemme License
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.